Selecting a viral load threshold for routine monitoring in resource-limited settings: optimizing individual health and population impact

Tanya M Ellman1,2, Bereket Alemayehu1, Elaine J Abrams1,3,4, Stephen Arpadi1,3,4, Andrea A Howard1,4 and Wafaa M El-Sadr1,4

© Copyright 2017 The Authors. Journal of the International AIDS Society published by John Wiley & sons Ltd on behalf of the International AIDS Society. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Keywords: viral load; HIV monitoring; resource limited setting; threshold; antiretroviral therapy; scale-up

The routine use of HIV viral load tests for monitoring patients on antiretroviral therapy (ART) in resource-limited settings has the potential to greatly benefit those with HIV infection as well as public health in general. Declines in viral load after ART initiation result in improved clinical outcomes [1,2] and viral load testing has therefore been considered the gold standard for measuring ART response in high-resource settings for many years [3]. Reductions in viral load also reduce the risk of perinatal [4] and sexual transmission of HIV [5]. However, availability of viral load testing has been limited in resource-limited settings where less sensitive and specific clinical and immunologic measures have largely been used to determine response to therapy; as of 2013 it was estimated that less than 20% of ART patients in Africa receive routine viral load testing [6,7]. In the past few years, enormous efforts have been made to scale-up availability of viral load testing for routine monitoring, however, some countries remain with little access, others are testing low proportions of patients on ART, and only a few are testing the majority of their ART patients [8,9]. Further, the impact of this recent viral load scale-up on clinical and public health outcomes are yet to be determined.

While initial studies in resource-limited settings found no mortality benefit when comparing viral load to CD4 count for monitoring [10,11], the rationale for monitoring viral load in patients on ART is based on several factors that pertain to both individual patient management as well as optimizing population health. Viral load testing can find individuals who might benefit from additional adherence support and leads to earlier and more accurate identification of treatment failure than clinical and immunologic indicators [10,12,13]. This allows for appropriate antiretroviral regimen selection and improved outcomes for individual patients, and provides a public health benefit through more appropriate allocation of second-line medications. Prompt detection of treatment failure through viral load monitoring may also prevent emergence of drug resistance mutations, providing benefit to the individual in settings where antiretroviral drug options are limited, and also at the population level by limiting transmission of drug-resistant virus [14].

The World Health Organization (WHO) guidelines recommend the use of viral load as the preferred method for monitoring treatment response over clinical and immunological approaches, and define virologic failure with a threshold of 1000 copies/ml [15]. The selection of this threshold has generated debate as to whether the desired goals of routine viral load monitoring, on individual and public health levels, will be achieved by using the 1000 copies/ml threshold and whether it will prove optimal across patient populations such as infants, children, adolescents, and pregnant and breastfeeding women.

In most resource-rich contexts, the goal of ART is to achieve viral suppression, usually defined as below the limit of detection of the assay (e.g. <20, <25, <37, <40 copies/ml) [16]. While studies show that transient episodes of viremia that subsequently return to below the limit of detection, often called “blips,” do not predict subsequent virologic failure [17,18], persistent low-level viremia carries some increase in risk of emergence of drug resistance and subsequent virologic failure [18,19]. Data show that persistent low-level viremia between 50 and 999 copies/ml, especially at the higher end of that range, is associated with an increased risk of resistance mutations, particularly M184I/V and K103N [19], which may impact effectiveness of first-line regimens most commonly used in resource-limited settings. Persistent viremia below 1000 copies/ml has also been noted to be associated with an increased risk of virologic failure [18], including with viral load levels as low as 50 to 199 copies/ml that persist for at least six months [20].

At the same time, there is also evidence to support the selection of a viral load threshold of 1000 copies/ml, particularly in resource-limited settings. Though the optimal value is not known, a viral load below 1000 copies/ml is associated
with a low risk of disease progression [21] and with a decrease in HIV transmission. Available data demonstrate that sexual transmission is very unlikely with a viral load <1700 copies/ml and even less likely with a viral load <400 copies/ml [22–24], and mother-to-child transmission is around one percent in women on antiretroviral drugs with a viral load <1000 copies/ml [4]. As a result, using a threshold of 1000 copies/ml appears to provide both individual and public health benefits while also simplifying the approach to routine viral load monitoring.

The choice of threshold for viral load among patients on ART in resource-limited settings is also influenced by available technology for viral load measurement. Use of dried blood spots (DBS) for viral load testing is a promising approach which offers advantages related to ease of specimen collection and handling, and allows for specimen transport without a cold chain, however, its use also impacts the choice of viral load threshold. Adapting laboratory viral load assays to accommodate DBS specimens poses specific technical challenges, such as lower sensitivity due to the lower specimen volume, differences in efficiency of nucleic acid extraction, and presence of amplification inhibitors such as hemoglobin [25]. As a result, lower limits of detection using DBS are much higher than those of plasma even for the same assay. In addition, amplification of cell-associated DNA or RNA in DBS reduces the specificity of DBS viral load testing [25].

The specific issues related to DBS measurement led to an initial reluctance to use the 1000 copies/ml threshold for DS. Thus, the WHO 2013 guidelines suggest considering a threshold of 3000 to 5000 copies/ml for such specimens [15]. However, advances in technology such as the introduction of RNA-specific extraction and amplification procedures to commercial kits have improved the specificity of DBS-based viral load testing [26]. Furthermore, a systematic review demonstrated acceptable performance characteristics for DBS compared to plasma for most technologies at the 1000 copies/ml threshold [7]. Therefore, the recent WHO guidelines recommend the threshold of 1000 copies/ml for viral load testing through DBS on most laboratory-based platforms [7,26], when there are operational barriers to using plasma. This threshold was recommended for all viral load methodologies, whether plasma or DBS-based, in order to simplify the training of diverse clinical providers and to enable the consistent and accurate implementation of viral load monitoring. However, there is an urgent need for additional data on the performance of DBS specimens using a viral load threshold of 1000 copies/ml in routine program settings, as well as data on the outcomes of patients with the use of this threshold for viral load monitoring.

Implementation of viral load testing for routine monitoring of ART response in resource-limited settings has the potential to lead to improved individual patient outcomes as well as to decreased risk of HIV transmission, potentially changing the trajectory of the HIV epidemic. While treatment experts advocate for the use of the lowest possible viral load threshold as the goal of HIV treatment, those with interest in the public health impact of viral load monitoring support the use of the 1000 copies/ml threshold as a pragmatic choice. The latter is offered as a compromise between the ideal for the individual and the need for a focus on achieving the greater good.

Moving forward, it will be particularly important to carefully evaluate the effect of use of the 1000 copies/ml threshold in terms of individual and population impacts. Such data will be critically important in informing future recommendations and guidelines. Most importantly, while viral load scale-up is an important priority, it is critical that it be coupled with ensuring access to such testing for all HIV-positive patients on treatment and effective utilization of results, irrespective of the viral load threshold selected, in order to achieve the promise of HIV treatment.

AUTHORS’ AFFILIATIONS
1 Mailman School of Public Health, ICAP at Columbia University, New York, NY, USA; 2 Division of Infectious Diseases, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, USA; 3 Department of Pediatrics, College of Physicians and Surgeons, Columbia University, New York, NY, USA; 4 Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.

COMPETING INTERESTS
Authors have no competing interests to declare.

AUTHOR’S CONTRIBUTIONS
TME, WMES, and EJA conceptualized the paper. TME drafted the manuscript with key contributions from BA, SA, AAH, WMES, and EJA. All authors have read and approved the final manuscript.

REFERENCES
1. Marschner IC, Collier AC, Coombs RW, D’Aquila RT, DeGruttola V, Fischl MA, et al. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis. 1998;177(1):40–7.
2. Thiebaut R, Morlat P, Jacqmin-Gadda H, Neau D, Mercie P, Dabis F, et al. Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. Groupe d’Epidemiologie du SIDA en Aquitaine (GECSA). AIDS. 2000;14(8):971–8.
3. Carpenter CC, Fischl MA, Hamner SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society–USA panel. JAMA. 1997;277(24):1962–9.
4. Ioannidis JP, Abrams EJ, Ammann A, Buller Y, Goedert JJ, Gray L, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml. J Infect Dis. 2001;183(4):539–45.
5. Cohen MS, Chen YQ, McQuaid MG, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.
6. African Society for Laboratory Medicine. Viral Load Monitoring in African Treatment Programmes. 2013.
7. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd ed. Geneva, Switzerland: WHO; 2016.

TME, WMES, and EJA conceptualized the paper. TME drafted the manuscript with key contributions from BA, SA, AAH, WMES, and EJA. All authors have read and approved the final manuscript.

REFERENCES
1. Marschner IC, Collier AC, Coombs RW, D’Aquila RT, DeGruttola V, Fischl MA, et al. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis. 1998;177(1):40–7.
2. Thiebaut R, Morlat P, Jacqmin-Gadda H, Neau D, Mercie P, Dabis F, et al. Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. Groupe d’Epidemiologie du SIDA en Aquitaine (GECSA). AIDS. 2000;14(8):971–8.
3. Carpenter CC, Fischl MA, Hamner SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society–USA panel. JAMA. 1997;277(24):1962–9.
4. Ioannidis JP, Abrams EJ, Ammann A, Buller Y, Goedert JJ, Gray L, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml. J Infect Dis. 2001;183(4):539–45.
5. Cohen MS, Chen YQ, McQuaid MG, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.
6. African Society for Laboratory Medicine. Viral Load Monitoring in African Treatment Programmes. 2013.

7. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd ed. Geneva, Switzerland: WHO; 2016.

TME, WMES, and EJA conceptualized the paper. TME drafted the manuscript with key contributions from BA, SA, AAH, WMES, and EJA. All authors have read and approved the final manuscript.
13. Rawizza HE, Chaplin B, Meloni ST, Eisen G, Rao T, Sankale JL, et al. Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. Clin Infect Dis. 2011;53(12):1283–90.

14. Gupta RK, Hill A, Sawyer AW, Cozzi-Lepri A, von Wyl V, Yerly S, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis. 2009;9(7):409–17.

15. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva, Switzerland: WHO; 2013.

16. Panel on Antiretroviral Guidelines for Adults and Adolescents Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 2016.

17. Havlir DV, Bassett R, Levitan D, Gilbert P, Tebas P, Coller AC, et al. Prevalence and predictive value of intermittent viremia with combination hiv therapy. JAMA. 2001;286(2):171–9.

18. Ryscavage P, Kelly S, Li JZ, Harrigan PR, Taiwo B. Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients. Antimicrob Agents Chemother. 2014;58(7):3585–98.

19. Taiwo B, Gallien S, Aga E, Ribaudo H, Haubrich R, Kuritzkes DR, et al. Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy. J Infect Dis. 2011;204(4):S15–20.

20. Laprise C, de Pokomandy A, Baril JC, Dufresne S, Trottier H. Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation. Clin Infect Dis. 2013;57(10):1489–96.

21. Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE), Mocroft A, Reiss P, et al. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/μL? Clin Infect Dis. 2010; 51(5): 611–9.

22. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342(13):921–9.

23. Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, Wabwire-Mangen F, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet. 2001;357(9263):1149–53.

24. Loutfy MR, Wu W, Letchumanan M, Bondy L, Antoniou T, Margolese S, et al. Systematic review of HIV transmission between heterosexual serodiscordant couples where the HIV-positive partner is fully suppressed on antiretroviral therapy. PLoS ONE. 2013;8(2):e55747.

25. Parkin NT. Measurement of HIV-1 viral load for drug resistance surveillance using dried blood spots: literature review and modeling of contribution of DNA and RNA. AIDS Rev. 2014;16(3):160–71.

26. WHO. Technical and operational considerations for implementing HIV viral load testing: interim technical update. Geneva, Switzerland: WHO; 2014.